We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Nanoneedle start-ups are traversing the biotech valley of death — from fundamental university research into commercial development in advanced therapeutics and diagnostics. How can academics make the most of this opportunity?
